Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
respiratory tract diseases | D012140 |
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Imfinzi | durvalumab | AstraZeneca UK Ltd | N-761069 RX | 2017-05-01 | 2 products |
Brand Name | Status | Last Update |
---|---|---|
imfinzi | Biologic Licensing Application | 2023-06-16 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
transitional cell carcinoma | — | D002295 | — |
Expiration | Code | ||
---|---|---|---|
durvalumab, Imfinzi, AstraZeneca UK Ltd | |||
2029-10-21 | Orphan excl. |
Code | Description |
---|---|
J9173 | Injection, durvalumab, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 37 | 95 | 31 | 2 | 15 | 167 |
Neoplasms | D009369 | — | C80 | 40 | 29 | — | 1 | 2 | 58 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 13 | 35 | 3 | 1 | 5 | 49 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 23 | 30 | 1 | — | 1 | 44 |
Hepatocellular carcinoma | D006528 | — | C22.0 | 11 | 26 | 6 | — | 4 | 41 |
Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 9 | 22 | 5 | — | 4 | 35 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 17 | 21 | 3 | — | 1 | 35 |
Small cell lung carcinoma | D055752 | — | — | 6 | 16 | 4 | — | 3 | 29 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 15 | 18 | 1 | — | — | 26 |
Urinary bladder neoplasms | D001749 | — | C67 | 10 | 19 | 2 | — | — | 26 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 8 | 14 | 2 | — | 1 | 21 |
Sarcoma | D012509 | — | — | 7 | 10 | 1 | — | — | 14 |
Biliary tract neoplasms | D001661 | — | C24.9 | 3 | 12 | 1 | — | — | 14 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 17 | 26 | — | — | — | 34 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 17 | 23 | — | — | — | 32 |
Triple negative breast neoplasms | D064726 | — | — | 10 | 13 | — | — | — | 20 |
Melanoma | D008545 | — | — | 11 | 9 | — | — | 2 | 18 |
Head and neck neoplasms | D006258 | — | — | 11 | 12 | — | — | 1 | 16 |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | 7 | 12 | — | — | — | 14 |
Cholangiocarcinoma | D018281 | — | C22.1 | 3 | 12 | — | — | — | 14 |
Prostatic neoplasms | D011471 | — | C61 | 4 | 9 | — | — | — | 11 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | 7 | 7 | — | — | — | 11 |
Esophageal neoplasms | D004938 | — | C15 | 4 | 9 | — | — | — | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
Leukemia myeloid chronic atypical bcr-abl negative | D054438 | — | C92.2 | 1 | — | — | — | — | 1 |
Myeloid leukemia chronic-phase | D015466 | — | — | 1 | — | — | — | — | 1 |
Thrombocytosis | D013922 | HP_0001894 | D75.83 | 1 | — | — | — | — | 1 |
Polycythemia | D011086 | EFO_0005804 | D75.1 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | — | 2 | 2 |
Myocarditis | D009205 | — | I51.4 | — | — | — | — | 2 | 2 |
Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | — | 2 | 2 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | — | — | — | 1 | 1 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | — | — | 1 | 1 |
Pericarditis | D010493 | EFO_0007427 | I30 | — | — | — | — | 1 | 1 |
Vasculitis | D014657 | HP_0002633 | — | — | — | — | — | 1 | 1 |
Myositis | D009220 | EFO_0000783 | G72.49 | — | — | — | — | 1 | 1 |
Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | — | — | 1 | 1 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
Drug common name | Durvalumab |
INN | durvalumab |
Description | Durvalumab (human mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | >5X8M:B|durvalumab heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLY
LQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTV
SWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH
>5X8M:C|durvalumab light chain
EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 5X8M, 5XJ4 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3301587 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11714 |
UNII ID | 28X28X9OKV (ChemIDplus, GSRS) |